The nation of Zimbabwe has declined a substantial US health deal worth $367m (£272m) spanning five years over the United States' demand for sensitive biological samples.
This rejection became public after a government memo dated December was disclosed, indicating that President Emmerson Mnangagwa felt the arrangement was "skewed".
An official representative later stated that the United States was seeking genetic material for research and commercial purposes while refused to share the benefits from future medical innovations.
"We will now turn to the difficult and regrettable process of scaling back our health assistance in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy said the US had furnished over $1.9bn for health programmes to Zimbabwe during the past two decades.
A physicians' group in Zimbabwe has urged continued negotiations to find a deal agreeable to all parties so the country's critical HIV treatment initiative can proceed.
Wider Implications
This rejection follows a similar situation in neighbouring Kenya, where a court suspended a similar deal with the US after concerns were raised about the security of Kenyans' health data.
Since returning to the presidency recently, US President Donald Trump has slashed foreign aid and shut down the key foreign aid agency.
The agency had administered aid for the American government, but Trump claimed its spending was "inefficient" and his government was pursuing government-to-government agreements to boost transparency and responsibility.
As per statements, Sixteen nations in Africa have to date agreed to these new agreements, constituting more than $18.3bn of fresh investment.
Details of the Declined Agreement
The money for Zimbabwe was intended to funded "tackling HIV/Aids, TB, malaria, maternal and child health, and disease outbreak preparedness.
"We are confident this partnership would have delivered immense benefits for the people of Zimbabwe, especially the 1.2 million presently on HIV treatment through American-funded programmes," Tremont commented.
However, government spokesperson Nick Mangwana argued the arrangement was "asymmetrical".
"Our nation was requested to surrender its biological resources and data for a long time, with no corresponding promise of access to any scientific breakthroughs – such as new medicines or tests – that might result from that provided information," his statement read.
"In essence, our nation would supply the raw materials for medical research without any certainty that the end products would be available to our citizens if a new disease outbreak arise."
Sovereignty and International Frameworks
He also said that the US's withdrawal from the World Health Organization (WHO) and its push of bilateral deals were upending structures previously established through the international organization.
Mangwana cited its Pathogen Access and Benefit Sharing scheme designed to manage potential pandemics.
"This mechanism is intended to ensure that when a country contributes its samples, the benefits – such as medicines and cures – are distributed fairly, not commercialised exclusively by those with the capability to create them."
These objections regarding the US deal "should not be misconstrued as opposition to America," Mangwana stressed.
"We welcome ongoing dialogue with our US partners on how future co-operation could be arranged in a way that honours the sovereignty and interests of each country."
Medical Community Reaction
Medical experts stated it recognised the government's concerns, but suggested that talks should continue considering a large portion of the country's HIV programmes relied on external financing.
"If technical issues arise, including those relating to information security or implementation frameworks, these can often be resolved through technical clarification and mutually agreed protections," it said.
This impasse emphasises the complex debate between receiving vital international aid and safeguarding national sovereignty in an increasingly interconnected world.